Related Experiment Video
Updated: Aug 4, 2026
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
TNP-470 antiangiogenic therapy for advanced murine neuroblastoma
E Nagabuchi1, W E VanderKolk, Y Une
1Division of Pediatric Surgery, Children's Hospital Research Foundation, Children's Hospital Medical Center, Cincinnati, OH 45299, USA.
Abstract:
The finding that angiogenesis plays an important role in the progression and metastasis of malignant tumors has led to the development of several antiangiogenic drugs. The authors report here an examination of the effect of the antiangiogenic agent TNP-470 on the growth, metastases, and survival of two differing murine neuroblastoma cell lines, TBJ and C1300. We found that TNP-470 significantly reduced primary tumor volumes in mice injected with either cell line. In addition, antiangiogenic therapy significantly reduced the size of axillary lymph node metastases in both groups as well as decreased the size of liver metastases in mice receiving TBJ neuroblastoma. TNP-470 treatment also improved animal survival. These data suggest that antiangiogenic therapy retards the growth of primary and metastatic murine neuroblastoma. We speculate that antiangiogenic therapy may be a useful therapeutic modality in the treatment of advanced neuroblastoma once side effects and appropriate dosage requirements are determined.
Insights
Antiangiogenic therapy with TNP-470 significantly reduced tumor growth and metastasis in murine neuroblastoma models. This treatment also improved animal survival, suggesting potential for advanced neuroblastoma treatment.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Angiogenesis is crucial for malignant tumor progression and metastasis.
- Antiangiogenic drugs are developed to target tumor vascularization.
Purpose of the Study:
- To evaluate the efficacy of the antiangiogenic agent TNP-470.
- To assess TNP-470's impact on neuroblastoma growth, metastasis, and survival in murine models.
Main Methods:
- Treatment of murine neuroblastoma cell lines (TBJ and C1300) with TNP-470.
- Monitoring of primary tumor volumes, lymph node and liver metastases.
- Assessment of animal survival rates.
Main Results:
- TNP-470 significantly reduced primary tumor volumes in both neuroblastoma cell lines.
- Antiangiogenic therapy decreased the size of lymph node and liver metastases.
- TNP-470 treatment led to improved survival in treated mice.
Conclusions:
- Antiangiogenic therapy with TNP-470 effectively retards primary and metastatic murine neuroblastoma growth.
- TNP-470 shows promise as a therapeutic strategy for advanced neuroblastoma.
- Further research is needed to determine optimal dosage and side effect profiles.
